Advertisement · 728 × 90
#
Hashtag
#FAERS
Advertisement · 728 × 90

While our @nejm.org Perspective focuses on #FAERS (FDA's passive drug safety surveillance system), the limitations to this database also apply to VAERS for vaccines. Current FDA leadership is using VAERS to make conclusions despite its many limitations & no scientific explanation. #MedSky

1 0 1 0
Aaron Rupar
@atrupar
Ron Johnson: "In 56 years of tracking Tylenol, there have been 39,540 death reported to FAIRS. That's 706 per year. For ivermectin -- remember the one that they said was so dangerous? -- in 29 years reporting, 493 deaths, 17 a year."

Aaron Rupar @atrupar Ron Johnson: "In 56 years of tracking Tylenol, there have been 39,540 death reported to FAIRS. That's 706 per year. For ivermectin -- remember the one that they said was so dangerous? -- in 29 years reporting, 493 deaths, 17 a year."

- Who sends reports to FAERS?

Healthcare professionals, consumers, and manufacturers submit reports to FAERS. FDA receives voluntary reports directly from healthcare professionals (such as physicians, pharmacists, nurses and others) and consumers (such as patients, family members, lawyers and others). Healthcare professionals and consumers may also report to the products’ manufacturers. If a manufacturer receives a report from a healthcare professional or consumer, it is required to send the report to FDA as specified by regulations.

+ How can I report an adverse event or medication error to FDA?

+ Can mandatory reporters submit adverse events electronically?

- Does FAERS data have limitations?

Yes, FAERS data does have limitations. First, there is no certainty that the reported event (adverse event or medication error) was due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. Furthermore, FDA does not receive reports for every adverse event or medication error that occurs with a product. Many factors can influence whether an event will be reported, such as the time a product has been marketed and publicity about an event. There are also duplicate reports where the same report was submitted by a consumer and by the sponsor. Therefore, FAERS data cannot be used to calculate the incidence of an adverse event or medication error in the U.S. population.

- Who sends reports to FAERS? Healthcare professionals, consumers, and manufacturers submit reports to FAERS. FDA receives voluntary reports directly from healthcare professionals (such as physicians, pharmacists, nurses and others) and consumers (such as patients, family members, lawyers and others). Healthcare professionals and consumers may also report to the products’ manufacturers. If a manufacturer receives a report from a healthcare professional or consumer, it is required to send the report to FDA as specified by regulations. + How can I report an adverse event or medication error to FDA? + Can mandatory reporters submit adverse events electronically? - Does FAERS data have limitations? Yes, FAERS data does have limitations. First, there is no certainty that the reported event (adverse event or medication error) was due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. Furthermore, FDA does not receive reports for every adverse event or medication error that occurs with a product. Many factors can influence whether an event will be reported, such as the time a product has been marketed and publicity about an event. There are also duplicate reports where the same report was submitted by a consumer and by the sponsor. Therefore, FAERS data cannot be used to calculate the incidence of an adverse event or medication error in the U.S. population.

🆘

Sen Ron Johnson has been misusing the FAERS "data" since COVID.

The FDA's website has always said he should not use their info this way.

fis.fda.gov/extensions/F...

#Wisconsin #wipolitics #wisdems #wisgop #Tylenol #FAERS #RFKJr #FDA #HHS #autism #DrOz #acetaminophen #WIGov

4 1 1 0
Preview
FDA Begins Real-Time Reporting of Adverse Event Data - OncoDaily FDA Begins Real-Time Reporting of Adverse Event Data / cancer, FAERS, FDA, FDA Adverse Event Reporting System, OncoDaily, Oncology, public health

FDA Begins Real-Time Reporting of Adverse Event Data
@fda.gov

oncodaily.com/voices/adver...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #AdverseEvents #AEs #FAERS

8 1 0 0
Preview
Visualization of FDA Adverse Drug Reaction Reports: Development and #usability Study of the VisDrugs Web Server Background: Adverse drug reactions (ADRs) are a major concern in drug safety and the FDA Adverse Event Reporting System (FAERS) provides valuable ADR data. However, analyzing FAERS data is complex and requires bioinformatics expertise. Despite the vast amount of ADR data available, there is a lack of user-friendly tools that enable efficient visualization and comparison of ADRs for researchers and healthcare professionals. Objective: This study aimed to develop VisDrugs, a web-based platform that simplifies ADR visualization and comparison using FAERS data. The platform was designed to assist researchers and clinicians in assessing drug safety through interactive and interpretable graphical representations of ADR patterns. Methods: FAERS data were extracted in ASCII format, covering the period from Q3 2014 to Q3 2024. Reports from healthcare professionals, where only a single drug was implicated, were aggregated and processed using R for statistical analysis and visualization. The results are presented on a web-based platform for interactive online analysis. The platform generates pie charts displaying the most frequently reported Preferred Terms (PTs) based on Medical Dictionary for Regulatory Activities (MedDRA) terminology and forest plots illustrating Reporting Odds Ratios (RORs) for these PTs. Results: Using Paxlovid (#covid19 treatment) and Hydroxychloroquine (anti-malaria drug) as case studies, we found that Paxlovid was predominantly associated with PTs related to #covid19, while Hydroxychloroquine demonstrated association with retinopathy and cardiomyopathy. The platform's subgroup analysis function elucidated that advanced age and female gender were correlated with an increased risk of Hydroxychloroquine-related retinopathy and cardiomyopathy. The majority of findings align with existing research, thereby validating the platform's utility. Clinical personnel have evaluated and refined the platform based on user feedback, confirming its efficacy in visualizing complex ADR data and identifying adverse effects across various drug subgroups. Conclusions: VisDrugs is a valuable tool for ADR analysis, offering an intuitive interface for exploring FAERS data. By visualizing and comparing ADRs, it helps researchers and healthcare providers assess drug safety efficiently. The platform’s demographic analysis features add insights into ADR variations by age and gender, supporting drug safety research. In the future, the website will include more subgroup or condition filtering options, offering personalized ADR analysis and comparison features to meet the diverse research needs of users.

JMIR Formative Res: Visualization of FDA Adverse Drug Reaction Reports: Development and #usability Study of the VisDrugs Web Server #AdverseDrugReactions #DrugSafety #FAERS #Bioinformatics #HealthTechnology

0 0 0 0
Post image

This study provides a comprehensive profile of #SacituzumabGovitecan (SG) toxicity based on #clinicaltrials, the #FAERS database, and the DDInter database, identifying several new #adverseeffects (AEs) and drug–drug interactions associated with SG. #medsky

Read more: buff.ly/o8vzuAZ

0 0 0 0
Post image

Pubs of @fda.gov #FAERS data have exploded since the making it public in 2018. The nature of spontaneous reports is such that these analyses should not be interpreted as causal & generally are not useful for patients & clinicians. Details at: www.medcentral.com/dermatology/...
#DermSky #MedSky

0 0 0 0
Excess Mortality in Alzheimer’s Patients on Anti-Aβ Monoclonal Antibodies Introduction It is unclear how the reported deaths of Alzheimer’s disease (AD) patients treated with the monoclonal antibodies lecanemab and aducanumab compare with background mortality rates.  M...

Excess Mortality in Alzheimer’s Patients on Anti-Aβ Monoclonal Antibodies

www.researchsquare.com/article/rs-5...

[A preprint, not yet peer-reviewed]

#aducanumab #lecanemab #FDA #FAERS mortality #Alzheimer

0 0 0 0